D.B. Root & Company’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $248K | Sell |
499
-155
| -24% | -$68.7K | 0.05% | 182 |
|
|
2026
Q1 | $292K | Sell |
654
-159
| -20% | -$74.1K | 0.07% | 156 |
|
|
2025
Q4 | $369K | Sell |
813
-144
| -15% | -$62.1K | 0.09% | 134 |
|
|
2025
Q3 | $375K | Sell |
957
-125
| -12% | -$52.2K | 0.1% | 129 |
|
|
2025
Q2 | $482K | Sell |
1,082
-27
| -2% | -$12.4K | 0.14% | 107 |
|
|
2025
Q1 | $538K | Buy |
1,109
+242
| +28% | +$113K | 0.17% | 95 |
|
|
2024
Q4 | $349K | Sell |
867
-44
| -5% | -$20.4K | 0.11% | 129 |
|
|
2024
Q3 | $424K | Sell |
911
-124
| -12% | -$59.6K | 0.14% | 105 |
|
|
2024
Q2 | $485K | Sell |
1,035
-359
| -26% | -$156K | 0.17% | 109 |
|
|
2024
Q1 | $583K | Buy |
1,394
+26
| +2% | +$11K | 0.2% | 103 |
|
|
2023
Q4 | $557K | Sell |
1,368
-162
| -11% | -$59.8K | 0.2% | 105 |
|
|
2023
Q3 | $532K | Sell |
1,530
-12
| -0.8% | -$4.2K | 0.21% | 107 |
|
|
2023
Q2 | $543K | Buy |
1,542
+57
| +4% | +$19.2K | 0.21% | 107 |
|
|
2023
Q1 | $468K | Buy |
1,485
+20
| +1% | +$6K | 0.18% | 111 |
|
|
2022
Q4 | $423K | Sell |
1,465
-28
| -2% | -$8.53K | 0.18% | 114 |
|
|
2022
Q3 | $432K | Buy |
1,493
+183
| +14% | +$52.7K | 0.2% | 109 |
|
|
2022
Q2 | $369K | Sell |
1,310
-1,964
| -60% | -$526K | 0.16% | 126 |
|
|
2022
Q1 | $854K | Sell |
3,274
-595
| -15% | -$141K | 0.32% | 78 |
|
|
2021
Q4 | $849K | Sell |
3,869
-64
| -2% | -$12.4K | 0.31% | 81 |
|
|
2021
Q3 | $713K | Sell |
3,933
-770
| -16% | -$150K | 0.28% | 101 |
|
|
2021
Q2 | $948K | Sell |
4,703
-64
| -1% | -$13.4K | 0.35% | 74 |
|
|
2021
Q1 | $1.02M | Buy |
4,767
+2,348
| +97% | +$516K | 0.4% | 59 |
|
|
2020
Q4 | $571K | Buy |
+2,419
| New | +$555K | 0.23% | 111 |
|
|
2020
Q1 | – | Sell |
-1,375
| Closed | -$301K | – | 205 |
|
|
2019
Q4 | $301K | Sell |
1,375
-15
| -1% | -$3.04K | 0.13% | 167 |
|
|
2019
Q3 | $235K | Sell |
1,390
-780
| -36% | -$138K | 0.11% | 175 |
|
|
2019
Q2 | $397K | Buy |
2,170
+455
| +27% | +$79.5K | 0.18% | 138 |
|
|
2019
Q1 | $315K | Buy |
1,715
+135
| +9% | +$24.9K | 0.13% | 171 |
|
|
2018
Q4 | $262K | Sell |
1,580
-189
| -11% | -$32.7K | 0.13% | 163 |
|
|
2018
Q3 | $341K | Buy |
1,769
+154
| +10% | +$27.4K | 0.15% | 160 |
|
|
2018
Q2 | $274K | Buy |
1,615
+30
| +2% | +$4.65K | 0.13% | 171 |
|
|
2018
Q1 | $258K | Buy |
+1,585
| New | +$259K | 0.14% | 167 |
|
Other funds holding VRTX
D.B. Root & Company's VRTX Position: Q2 2026 in Review
D.B. Root & Company reduced its Vertex Pharmaceuticals (VRTX) stake by 24% in Q2 2026, selling an estimated $68.7K and leaving 499 shares worth $248K. The position accounts for 0.05% of the portfolio, ranked #182.
D.B. Root & Company first reported a position in VRTX in Q1 2018 and has held it in 31 quarters since. The position peaked at $1.02M in Q1 2021. 1,757 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.
- D.B. Root & Company held 499 shares of Vertex Pharmaceuticals worth $248K as of Q2 2026.
- D.B. Root & Company sold 155 Vertex Pharmaceuticals shares in Q2 2026, an estimated $68.7K.
- Vertex Pharmaceuticals made up 0.05% of D.B. Root & Company's portfolio in Q2 2026, its #182 holding.
- D.B. Root & Company first reported a position in Vertex Pharmaceuticals in Q1 2018 and has held it in 31 quarters since.
- D.B. Root & Company's Vertex Pharmaceuticals position peaked at $1.02M in Q1 2021.
- 1,757 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.
Based on D.B. Root & Company's 13F filing for Q2 2026, filed 13 Aug 2026.